Publication:
Kidney transplantation: is it a solution to endothelial dysfunction?

dc.contributor.coauthorUreche, Carina
dc.contributor.coauthorCovic, Alexandra M.
dc.contributor.coauthorSekmen, Mert
dc.contributor.coauthorCovic, Adrian
dc.contributor.departmentN/A
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.kuauthorTanrıöver, Cem
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileResearcher
dc.contributor.kuprofileUndergraduate Student
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid110580
dc.contributor.yokid368625
dc.contributor.yokidN/A
dc.date.accessioned2024-11-09T23:20:34Z
dc.date.issued2022
dc.description.abstractBackground Endothelial dysfunction is associated with elevated cardiovascular risk in patients with end-stage renal disease (ESRD). Kidney transplantation has demonstrated significant ability in reducing mortality and improving quality of life in recipients. Recent studies have also reported improvements in endothelial function following kidney transplantation; however, current literature is limited. Methods We performed a systematic review of PubMed/Medline, Web of Science, Scopus, Cochrane Library, and CINAHL databases for prospective cohort studies that assessed endothelial function prior to and following kidney transplantation via various clinical markers. Follow-up duration ranged from 1 month to 1 year. A meta-analysis of pooled data was conducted using random-effect models for four key markers: brachial artery flow-mediated dilatation (FMD), high-sensitivity C-reactive protein (hsCRP), nitroglycerin-mediated dilation (NMD), and adiponectin. Results We included nine studies in our final analysis with a total of 524 patients. Significant improvement of all four biomarkers was observed after transplantation. The mean difference was 2.81% (95% CI 1.92-3.71, p < 0.00001) for FMD, 17.27 mg/L (95% CI 5.82-28.72, p = 0.003) for hsCRP, 1.05%, (95% CI 0.56-1.54, p < 0.0001) for NMD, and 9.27 mu g/mL (95% CI 5.96-12.57, p < 0.00001) for adiponectin. Conclusion There is an immediate reversal of endothelial dysfunction in ESRD patients who undergo kidney transplantation, which may explain observed improvements in cardiovascular morbidity in transplant recipients. Future longitudinal studies are needed to understand possible re-emergence of endothelial dysfunction in the long-term postoperative period.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1007/s11255-022-03415-x
dc.identifier.eissn1573-2584
dc.identifier.issn0301-1623
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85142128388
dc.identifier.urihttp://dx.doi.org/10.1007/s11255-022-03415-x
dc.identifier.urihttps://hdl.handle.net/20.500.14288/10745
dc.identifier.wos886322600001
dc.keywordsKidney Transplantation
dc.keywordsEndothelial Function
dc.keywordsInflammation
dc.keywordsMortality
dc.keywordsAdiponectin
dc.keywordsRenal-Transplantation
dc.keywordsCardiovascular-Disease
dc.keywordsPlasma Adiponectin
dc.keywordsMicroparticles
dc.keywordsInflammation
dc.keywordsDialysis
dc.languageEnglish
dc.publisherSpringer
dc.sourceInternational Urology and Nephrology
dc.subjectUrology
dc.subjectNephrology
dc.titleKidney transplantation: is it a solution to endothelial dysfunction?
dc.typeReview
dspace.entity.typePublication
local.contributor.authorid0000-0002-1297-0675
local.contributor.authorid0000-0003-0190-2746
local.contributor.authorid0000-0001-5536-0263
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÇöpür, Sidar
local.contributor.kuauthorTanrıöver, Cem

Files